"STICH: CABG Survival Benefit Doesn't Hinge on Myocardial Viability" - Nicole Lou
Viable myocardium doesn't boost long-term benefit from coronary artery bypass grafting in patients with ischemic cardiomyopathy and coronary artery disease, a STICH trial analysis found. Similar findings were reported for the secondary endpoints of death from cardiovascular causes and combined all-cause mortality and cardiovascular hospitalization. “I must say I would have expected that presence of ischemia/viability would have an important implication for outcomes,” said Roxana Mehran, MD, director of interventional cardiovascular research and clinical trials at the Zena and Michael A. Weiner Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai. She added, “One wonders whether if there were more patients with viability in that trial, an important survival benefit to PCI over optimal medical therapy in stable angina might have turned up.”
— Roxana Mehran, MD, Director, Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Weiner Cardiovascular Institute, Professor, Medicine, Cardiology, Population Health Science and Policy, Icahn School of Medicine at Mount Sinai
Coronary Stent Patients May Not Need Long-Term Aspirin
Sep 26, 2019 View All Press Releases